

Christopher A Green

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3345777/publications.pdf>

Version: 2024-02-01

61
papers

24,076
citations

117453

34
h-index

138251

58
g-index

67
all docs

67
docs citations

67
times ranked

40357
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexamethasone in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 693-704.	13.9	8,063
2	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , The, 2021, 397, 99-111.	6.3	3,887
3	Features of 20% 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. <i>BMJ</i> , The, 2020, 369, m1985.	3.0	2,474
4	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> , The, 2021, 397, 1637-1645.	6.3	1,374
5	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet</i> , The, 2021, 397, 881-891.	6.3	979
6	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
7	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. <i>BMJ</i> , The, 2020, 370, m3339.	3.0	779
8	Lopinavirâ€“ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> , The, 2020, 396, 1345-1352.	6.3	569
9	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1351-1362.	6.3	540
10	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 398, 2258-2276.	6.3	519
11	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet</i> , The, 2021, 398, 856-869.	6.3	430
12	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. <i>Lancet</i> , The, 2021, 397, 2049-2059.	6.3	391
13	Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 546.	3.8	229
14	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , The, 2021, 2, e354-e365.	3.4	216
15	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet</i> , The, 2021, 398, 981-990.	6.3	214
16	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
17	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	5.6	161
18	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 349-359.	5.2	161

#	ARTICLE	IF	CITATIONS
19	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
20	Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. <i>Archives of Disease in Childhood</i> , 2016, 101, 140-146.	1.0	157
21	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet, The</i> , 2021, 398, 223-237.	6.3	110
22	Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. <i>Science Translational Medicine</i> , 2015, 7, 300ra126.	5.8	109
23	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
24	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 773-785.	5.2	78
25	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. <i>Lancet, The</i> , 2021, 398, 1037-1038.	6.3	75
26	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines MO1ZH09 with Placebo and Ty21a. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004926.	1.3	67
27	Respiratory syncytial virus: diagnosis, prevention and management. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611986579.	1.1	65
28	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , 2021, 3, e498-e506.	2.2	58
29	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	56
30	Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. <i>BMJ Open</i> , 2015, 5, e008748.	0.8	49
31	Best practice in the prevention and management of paediatric respiratory syncytial virus infection. <i>Therapeutic Advances in Infectious Disease</i> , 2016, 3, 63-71.	1.1	49
32	COVID-19: time for a bold new strategy for medical education. <i>Medical Education Online</i> , 2020, 25, 1764741.	1.1	43
33	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2022, 84, 795-813.	1.7	43
34	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. <i>Journal of Infection</i> , 2019, 78, 382-392.	1.7	42
35	A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. <i>Journal of Infection</i> , 2015, 71, 326-337.	1.7	40
36	Inherited metabolic diseases in the sudden infant death syndrome. <i>Archives of Disease in Childhood</i> , 1991, 66, 1315-1317.	1.0	35

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. <i>Thorax</i> , 2022, 77, 259-267.	2.7	34
38	Airway response to respiratory syncytial virus has incidental antibacterial effects. <i>Nature Communications</i> , 2019, 10, 2218.	5.8	30
39	Priorities for developing respiratory syncytial virus vaccines in different target populations. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
40	Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 531.	3.7	29
41	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. <i>Thorax</i> , 2022, 77, 606-615.	2.7	24
42	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1049-1060.	5.2	24
43	Towards personalized guidelines: using machine-learning algorithms to guide antimicrobial selection. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2677-2680.	1.3	23
44	Swine flu: a Birmingham experience. <i>Clinical Medicine</i> , 2009, 9, 534-538.	0.8	22
45	Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. <i>BMC Health Services Research</i> , 2021, 21, 566.	0.9	22
46	Humoral and cellular immunity to RSV in infants, children and adults. <i>Vaccine</i> , 2018, 36, 6183-6190.	1.7	20
47	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e220-e234.	5.9	20
48	Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. <i>Archives of Disease in Childhood</i> , 2013, 98, 248-251.	1.0	18
49	RSV vaccine use – the missing data. <i>Expert Review of Vaccines</i> , 2016, 15, 149-152.	2.0	17
50	Chest radiography findings in adults with pandemic H1N1 2009 influenza. <i>British Journal of Radiology</i> , 2010, 83, 499-504.	1.0	14
51	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac179.	0.4	10
52	Vaccination against Respiratory Syncytial Virus. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2020, 43, 182-192.	2.6	6
53	COVID-19: medical students in clinical research. <i>Clinical Teacher</i> , 2021, 18, 79-81.	0.4	6
54	The journey towards safely restarting faecal microbiota transplantation services in the UK during the COVID-19 era. <i>Lancet Microbe</i> , The, 2021, 2, e133-e134.	3.4	5

#	ARTICLE	IF	CITATIONS
55	Multi-modality detection of SARS-CoV-2 in faecal donor samples for transplantation and in asymptomatic emergency surgical admissions. <i>F1000Research</i> , 2021, 10, 373.	0.8	5
56	The Volunteers in Research programme: supporting COVID-19 research and improving medical training in parallel. <i>Clinical Medicine</i> , 2021, 21, 182-188.	0.8	5
57	Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. <i>MSphere</i> , 2022, 7, e0067421.	1.3	5
58	A T-cell-dependent humoral immune response is preserved during the administration of the nerve agent pre-treatment pyridostigmine bromide in a murine model. <i>International Immunopharmacology</i> , 2005, 5, 525-540.	1.7	2
59	Case Report: Subarachnoid Hemorrhage and Eosinophilic Meningitis due to Disseminated Fascioliasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 574-577.	0.6	2
60	CHANGING ANTIBIOTIC PROPHYLAXIS FOR TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSIES: ARE WE PUTTING OUR PATIENTS AT RISK?. <i>BJU International</i> , 2011, 108, E155.	1.3	0
61	Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. <i>Vaccine</i> , 2018, 36, 6988-6994.	1.7	0